Hola,
Are you new here?

GO-DS21

financed

Gene overdosage and comorbidities during the early lifetime in Down Syndrome

The aim of the project is to elucidate etiological mechanisms involved in the appearance of obesity, and intellectual disability comorbidities in Down syndrome (DS). With its incidence of 1 in 1000 births, DS offers a great opport... see more

30/06/2025

CERBM-GIE

6M€

Project Budget: 6M€

Project leader

CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET M... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 12 Participantes

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2019-11-22

SC1-BHC-01-2019: Understanding causative mechanisms... Specific Challenge:The increasing number of individuals with co-and multimorbidities poses an urgent...

I+D

Cerrada does 6 years

0% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

12 Participantes

CERBM-GIE

1.03M€ | Leader

FERRER INTERNACIONAL

717.91K€ | participant

CONCENTRIS RESEARCH MANAGEME...

370.00K€ | participant

FUNDACIO PRIVADA CENTRE DE R...

554.56K€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 67 months Date Start: 2019-11-22
End date: 2025-06-30

Project leader

CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET M... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 6M€

participation deadline Sin fecha límite de participación.

Project description The aim of the project is to elucidate etiological mechanisms involved in the appearance of obesity, and intellectual disability comorbidities in Down syndrome (DS). With its incidence of 1 in 1000 births, DS offers a great opportunity to uncover common/novel mechanisms because it is associated with a higher risk to develop several obesity, and intellectual disability. The increased risk to develop this combination of comorbidities in DS, suggests that specific genetic or epigenetic mechanisms associated with trisomy 21 (the cause of DS) predispose to this comorbidity. For this aim, GO-DS21 will have the following objectives: 1) To determine age-related comorbidity patterns observed over the early lifetime (before age 45) in persons with Down syndrome (WP1). 2) To identify specific physiological biomarkers (WP4), and regulatory and epigenetic signatures (WP5) in human, cellular and animal models. 3) To decipher the contribution of environmental factors (stress, diet, exercise) to trisomy 21 obesity/ID comorbidities in preclinical models (WP2, 3). 4) To investigate the effects of overdosage of three Hsa21 candidate genes (DYRK1A, MRAP, NRIP1) to explain comorbid patterns in mouse models (WP3). 5) To integrate multilevel data from human patients, preclinical and cellular models across different spatial and temporal scales of biological complexity using computational biology models and machine learning approaches (WP6). 6) To design new therapeutic interventions to reduce the penetrance of comorbidities in preclinical models (WP3 and WP4). This approach will help to improve diagnosis and understanding of prognostic factors, and will establish recommendations and targeted interventions to prevent or minimise comorbidities in persons with DS (WP7). Beyond the impact for patients with DS we expect that findings of this project will also be beneficial for patients in the general population.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers